Granules Life Sciences Receives VAI Classification following US FDA Inspection

Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI).

The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025.

The inspection is now closed, and no regulatory action has been recommended.

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited, said, "While receiving the classification is a step in the right direction, we recognize that quality is not a one-time milestone but an ongoing commitment. It will continue to remain a core pillar of utmost importance across all Granules sites, guiding our actions, investments, and culture every day."

This development further strengthens Granules India's finished dosage manufacturing capabilities by enabling multi-site manufacturing for the approved products.

Shares of Granules India Limited was last trading in BSE at Rs. 621.15 as compared to the previous close of Rs. 623.25. The total number of shares traded during the day was 23165 in over 1323 trades.

The stock hit an intraday high of Rs. 626.20 and intraday low of 600.25. The net turnover during the day was Rs. 14415970.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 Pharmaceuticals GranulesLifeSciences USFDA Inspection VAI Shamirpet Telangana